Banzel Mobile Logo A Challenging Form of Epilepsy Seizure Types in LGS LGS Patient Profiles Pivotal Trial Design Efficacy of BANZEL® in Seizure Reduction Seizure Severity Rating Responder Rates Adverse Reactions Mechanism of Action/Pharmacokinetics Drug Interactions Dosing Samples Savings & Coverage BANZEL® Connect

BANZEL is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in pediatric patients 1 year of age and older, and in adults.

Prescribing Information Important Safety Information For Patients

INFORMATION AND RESOURCES TO HELP PATIENTS ACCESS BANZEL®

Help patients save with the BANZEL® Savings Card

Banzel savings card

*Eligible patients pay the first $25 and Eisai Inc. will pay up to $275 per month.

Patients can activate or register a card online at www.BanzelCard.com or by calling 1-855-EISAI-4-U

*Restrictions apply. Not available to patients enrolled in federal or state healthcare program, including Medicare, Medicaid, Medigap, VA, DoD, or TRICARE programs. Complete terms and conditions available at www.BanzelCard.com.

Resources available from the Eisai Assistance Program

Financial Assistance image

Financial Assistance

Support Savings Card enrollment for eligible patients and provide Patient Assistance Program (PAP) information for eligible patients. ►

Prior Authorization Support Image

Prior Authorization Support

Required steps identified and proper forms provided.►

Appeal Initiation Management For Eligible Patients image

Appeal Initiation Management For Eligible Patients

Insurance-specific requirements verified plus resources and sample templates available. Process monitored and results communicated. ►

Benefit Investigation Image

Benefit Investigation

Insurance coverage and any coverage restrictions detailed plus prior authorization (PA) requirements determined. Access to drug options provided and expected out-of-pocket (OOP) costs calculated. ►

◄Previous Next: BANZEL® CONNECT►
Efficacy icon

EFFICACY ►

Learn about the efficacy of BANZEL® (rufinamide) in the pivotal trial
Register now icon

REGISTER NOW ►

Register now to receive updates and resources
Banzel Connect icon

BANZEL® CONNECT ►

Take part in this
peer-to-peer program